Back to Newsroom

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 21, 2017 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, announced today that the Company will present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26 at 2:30 p.m. EDT, in Track 2-Odeon at the Sofitel Hotel, New York. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs.
READ MORE…